Skip to content

Journal of Psychiatric Practice

ISSN 1538-1145

16 papers in the library · 491 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Dispositional Mindfulness and Perceived Stress in Psychiatric and Nonpsychiatric Physicians: A Facet-level Pilot Study

Journal of Psychiatric Practice May 1, 2026 Mohammad Asif Sheikh

Objectives: Perceived stress is a significant concern among health care professionals, with potential consequences for mental health and clinical performance. This study examined associations between dispositional mindfulness and perceived stress among Indian physicians working in psychiatric and nonpsychiatric specializations within hierarchical systems with limited institutional support....

Intravenous Ketamine Followed by Intranasal Esketamine in 2 Subsequent Treatment-resistant Depressive Episodes: Insights From a Case Series.

Journal of Psychiatric Practice September 1, 2025 Matteo Carminati, Mattia Tondello, Barbara Barbini et al. 2 citations

Treatment-resistant depression (TRD) remains a relevant issue in psychiatric practice, driving the exploration of innovative therapeutic alternatives. Ketamine and its enantiomer, esketamine, are emerging as treatments known for their effectiveness as rapid-acting antidepressants. Although previous comparative studies have highlighted some differences in their effects, they did not concurrently...

Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder.

Journal of Psychiatric Practice May 1, 2025 Marc J. Weintraub, David J. Miklowitz, Jessica K Jeffrey

We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major depressive disorder. Both patients participated in an open trial involving 2 drug administration sessions separated by one month (10 and 25 mg, respectively) along with 12 sessions of cognitive behavioral therapy. The first of the 2 patients had...

Commentary on Nitrous Oxide: Weighing the Toxic Neuropsychiatric Effects of Abuse Against Potential Therapeutic Benefits for Psychiatric Disorders.

Journal of Psychiatric Practice May 1, 2025 Amir Garakani

Nitrous oxide (N2O), an anesthetic gas used for dental procedures, has recently become increasingly recognized as a potential drug of misuse and abuse, with an increasing number of case studies reporting serious adverse effects, including megaloblastic anemia, myelopathy, neuropathy, subacute combined degeneration, psychosis, and even death. There is also growing research support for the use of...

Recurrent Serotonin Syndrome After Ketamine-assisted Electroconvulsive Therapy: A Case Report and Review of the Literature.

Journal of Psychiatric Practice May 1, 2024 Aniruddha Deka, Emmanuel Joseph, Neha Sharma et al. 3 citations

Serotonin (5-HT) syndrome (SS) consists of changes in mental status as well as autonomic and neuromuscular changes. Though not well understood, serotonergic pathways have been implicated in the mechanism of action of electroconvulsive therapy (ECT). Ketamine has been used as an induction agent in ECT and as therapy for treatment-resistant depression. Utilizing a case report and literature...

Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans.

Journal of Psychiatric Practice March 1, 2024 Brian S. Barnett 5 citations

For more than 2 decades, intravenous ketamine has been demonstrated to have rapid antidepressant effects. However, access to this generic drug is limited due to insurers claiming it is "experimental" because ketamine does not have a Food and Drug Administration indication for depression. In contrast, intranasal esketamine, an enantiomer of ketamine, is approved by the Food and Drug...

How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.

Journal of Psychiatric Practice March 1, 2024 Sheldon H. Preskorn

This column focuses on the status of intravenous racemic ketamine for the treatment of patients suffering from a form of major depressive disorder that does not respond to trials of currently available biogenic amine antidepressants. To provide context, the column reviews the 3 pivotal elements of the usual Food and Drug Administration (FDA) drug approval process: (1) the unmet medical need...

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.

Journal of Psychiatric Practice September 1, 2023 Amir Garakani, Jeanne L Alexander, Calvin R Sumner et al. 6 citations

There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within the research community. Increasing numbers of studies evaluating psychedelics for depression, anxiety, posttraumatic stress disorder, and substance use disorders have been conducted or are underway. While discussing psychedelics in general, the focus...

Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine

Journal of Psychiatric Practice November 1, 2021 Amir Garakani

Treatment-resistant depression (TRD) may be responsive to interventions beyond antidepressants including brain stimulation such as electroconvulsive therapy (ECT) or to ketamine or esketamine, the latter of which is approved for TRD in an intranasal form. The 3 cases presented in this issue deal with an array of clinical considerations in treating patients with TRD, including the use of ECT in...

Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials

Journal of Psychiatric Practice March 1, 2021 Sheldon H. Preskorn 3 citations

This column reviews the development of intranasal esketamine with particular emphasis on the consistency of the clinical trial results. In the process, it illustrates methodological issues important in the approval process by an agency such as the United States Food and Drug Administration. Topics covered include the importance of study design, the nature of the comparator, and the prespecified...

Hallucinogens and Their Therapeutic Use: A Literature Review.

Journal of Psychiatric Practice September 1, 2019 Matthew J Begola, Jason E Schillerstrom 20 citations

The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including...

Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.

Journal of Psychiatric Practice July 1, 2018 Lai Fong Chan, Choon Leng Eu, Shean Yih Soh et al. 18 citations

Ketamine has shown effectiveness as a rapid-acting antidepressant with antisuicidal effects in terms of reduction of suicidal ideation in the short term. However, the evidence for long-term maintenance ketamine therapy for treatment-resistant depression (TRD) and suicidal behavior is limited. This case series (N=13) highlights the role of adjunctive serial maintenance ketamine infusions in...

Efficacy of Ketamine in Bipolar Depression: Systematic Review and Meta-analysis.

Journal of Psychiatric Practice November 1, 2015 Ajay K Parsaik, Balwinder Singh, Darrow Khosh-Chashm et al. 42 citations Retracted

To consolidate the evidence from the literature to evaluate the role of ketamine in the treatment of bipolar depression. Major databases, including MEDLINE, EMBASE, Cochrane, and Scopus, were searched through October 2014, for studies reporting the role of ketamine in the treatment of bipolar depression. Only randomized controlled trials were included in the meta-analysis. We calculated...

Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, and Zen Meditation for Depression, Anxiety, Pain, and Psychological Distress

Journal of Psychiatric Practice July 1, 2012 William R. Marchand 309 citations

Mindfulness has been described as a practice of learning to focus attention on moment-bymoment experience with an attitude of curiosity, openness, and acceptance. Mindfulness practices have become increasingly popular as complementary therapeutic strategies for a variety of medical and psychiatric conditions. This paper provides an overview of three mindfulness interventions that have...

Mindfulness-Based Cognitive Therapy for Bipolar Disorder

Journal of Psychiatric Practice November 1, 2011 Jonathan P. Stange, Lori Eisner, Britta K. Hölzel et al. 83 citations

Bipolar disorder is associated with impairments in cognition, including difficulties in executive functioning, even when patients are euthymic (neither depressed nor manic). The purpose of this study was to assess changes in self-reported cognitive functioning in patients with bipolar disorder who participated in an open pilot trial of mindfulness-based cognitive therapy (MBCT). Following MBCT,...

Music, psychotherapy, and the soul: thoughts on singing Beethoven's Missa Solemnis.

Journal of Psychiatric Practice May 1, 2011 Norman A Clemens

The author draws upon the experience of singing Beethoven's Missa Solemnis to explore the feeling states aroused by religious choral music, especially the Mass. He relates them to working with patients in psychotherapy around issues of dying, death, the "oceanic feeling" of the religious experience, the human quest for knowledge, and yearning for an eternal, intelligent, and all-knowing entity...